Literature DB >> 11237395

A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.

P Vahteristo1, H Eerola, A Tamminen, C Blomqvist, H Nevanlinna.   

Abstract

Germline mutations in BRCA1 and BRCA2 genes predispose to hereditary breast and ovarian cancer. Our aim was to find associations between the clinical characteristics and positive mutation status in 148 breast cancer families in order to predict the probability of finding a BRCA mutation in a family. Several factors were associated with mutations in univariate analysis, whereas in multivariate analysis (logistic regression with backward selection) only the age of the youngest breast cancer patient and the number of ovarian cancer cases in a family were independent predictors of BRCA mutations. A logistic model was devised to estimate the probability for a family of harbouring a mutation in either BRCA1 or BRCA2. Altogether, 63 out of 148 families (43%) and 28 out of 29 (97%) mutation carrier families obtained probabilities over 10%. The mean probability was 55% for mutation-positive families and 11% for mutation-negative families. The models by Couch et al (1997) and Shattuck-Eidens et al (1997) previously designed for BRCA1 were also tested for their applicability to distinguish carrier families with mutations in either gene. The probability model should be a useful tool in genetic counselling and focusing the mutation analyses, and thus increasing also the cost-effectiveness of the genetic screening. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11237395      PMCID: PMC2363799          DOI: 10.1054/bjoc.2000.1626

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  Evidence of founder mutations in Finnish BRCA1 and BRCA2 families.

Authors:  P Huusko; K Pääkkönen; V Launonen; M Pöyhönen; G Blanco; A Kauppila; U Puistola; H Kiviniemi; M Kujala; J Leisti; R Winqvist
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

2.  A low proportion of BRCA2 mutations in Finnish breast cancer families.

Authors:  P Vehmanen; L S Friedman; H Eerola; L Sarantaus; S Pyrhönen; B A Ponder; T Muhonen; H Nevanlinna
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

3.  A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.

Authors:  T Peelen; M van Vliet; A Petrij-Bosch; R Mieremet; C Szabo; A M van den Ouweland; F Hogervorst; R Brohet; M J Ligtenberg; E Teugels; R van der Luijt; A H van der Hout; J J Gille; G Pals; I Jedema; R Olmer; I van Leeuwen; B Newman; M Plandsoen; M van der Est; G Brink; S Hageman; P J Arts; M M Bakker; P Devilee
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

4.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

5.  BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history.

Authors:  K E Malone; J R Daling; J D Thompson; C A O'Brien; L V Francisco; E A Ostrander
Journal:  JAMA       Date:  1998-03-25       Impact factor: 56.272

6.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.

Authors:  G Parmigiani; D Berry; O Aguilar
Journal:  Am J Hum Genet       Date:  1998-01       Impact factor: 11.025

7.  BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.

Authors:  D Shattuck-Eidens; A Oliphant; M McClure; C McBride; J Gupte; T Rubano; D Pruss; S V Tavtigian; D H Teng; N Adey; M Staebell; K Gumpper; R Lundstrom; M Hulick; M Kelly; J Holmen; B Lingenfelter; S Manley; F Fujimura; M Luce; B Ward; L Cannon-Albright; L Steele; K Offit; A Thomas
Journal:  JAMA       Date:  1997-10-15       Impact factor: 56.272

8.  Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.

Authors:  P Vehmanen; L S Friedman; H Eerola; M McClure; B Ward; L Sarantaus; T Kainu; K Syrjäkoski; S Pyrhönen; O P Kallioniemi; T Muhonen; M Luce; T S Frank; H Nevanlinna
Journal:  Hum Mol Genet       Date:  1997-12       Impact factor: 6.150

9.  Population-based study of risk of breast cancer in carriers of BRCA2 mutation.

Authors:  S Thorlacius; J P Struewing; P Hartge; G H Olafsdottir; H Sigvaldason; L Tryggvadottir; S Wacholder; H Tulinius; J E Eyfjörd
Journal:  Lancet       Date:  1998-10-24       Impact factor: 79.321

10.  Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.

Authors:  F H Fodor; A Weston; I J Bleiweiss; L D McCurdy; M M Walsh; P I Tartter; S T Brower; C M Eng
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

View more
  34 in total

1.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Authors:  Pia Vahteristo; Jirina Bartkova; Hannaleena Eerola; Kirsi Syrjäkoski; Salla Ojala; Outi Kilpivaara; Anitta Tamminen; Juha Kononen; Kristiina Aittomäki; Päivi Heikkilä; Kaija Holli; Carl Blomqvist; Jiri Bartek; Olli-P Kallioniemi; Heli Nevanlinna
Journal:  Am J Hum Genet       Date:  2002-07-28       Impact factor: 11.025

2.  Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics.

Authors:  M de la Hoya; O Díez; P Pérez-Segura; J Godino; J M Fernández; J Sanz; C Alonso; M Baiget; E Díaz-Rubio; T Caldés
Journal:  J Med Genet       Date:  2003-07       Impact factor: 6.318

3.  A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.

Authors:  D G R Evans; D M Eccles; N Rahman; K Young; M Bulman; E Amir; A Shenton; A Howell; F Lalloo
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

4.  Practical implementation of frailty models in Mendelian risk prediction.

Authors:  Theodore Huang; Malka Gorfine; Li Hsu; Giovanni Parmigiani; Danielle Braun
Journal:  Genet Epidemiol       Date:  2020-06-07       Impact factor: 2.135

5.  Frailty Models for Familial Risk with Application to Breast Cancer.

Authors:  Malka Gorfine; Li Hsu; Giovanni Parmigiani
Journal:  J Am Stat Assoc       Date:  2013-12-01       Impact factor: 5.033

6.  Screening of HELQ in breast and ovarian cancer families.

Authors:  Liisa M Pelttari; Laura Kinnunen; Johanna I Kiiski; Sofia Khan; Carl Blomqvist; Kristiina Aittomäki; Heli Nevanlinna
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

7.  Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility.

Authors:  Yen Ling Low; Yuqing Li; Keith Humphreys; Anbupalam Thalamuthu; Yi Li; Hatef Darabi; Sara Wedrén; Carine Bonnard; Kamila Czene; Mark M Iles; Tuomas Heikkinen; Kristiina Aittomäki; Carl Blomqvist; Heli Nevanlinna; Per Hall; Edison T Liu; Jianjun Liu
Journal:  PLoS Genet       Date:  2010-07-01       Impact factor: 5.917

8.  Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene.

Authors:  Jirina Bartkova; Johanna Tommiska; Lenka Oplustilova; Kirsimari Aaltonen; Anitta Tamminen; Tuomas Heikkinen; Martin Mistrik; Kristiina Aittomäki; Carl Blomqvist; Päivi Heikkilä; Jiri Lukas; Heli Nevanlinna; Jiri Bartek
Journal:  Mol Oncol       Date:  2008-10-07       Impact factor: 6.603

9.  Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia.

Authors:  Wafa Troudi; N Uhrhammer; C Sibille; C Dahan; W Mahfoudh; C Bouchlaka Souissi; T Jalabert; L Chouchane; Y J Bignon; F Ben Ayed; A Ben Ammar Elgaaied
Journal:  J Hum Genet       Date:  2007-10-09       Impact factor: 3.172

10.  ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer.

Authors:  Sanna Siltanen; Kirsi Syrjäkoski; Rainer Fagerholm; Tarja Ikonen; Peter Lipman; Jacob Mallott; Kaija Holli; Teuvo L J Tammela; Heikki J Järvinen; Jukka-Pekka Mecklin; Kristiina Aittomäki; Carl Blomqvist; Joan E Bailey-Wilson; Heli Nevanlinna; Lauri A Aaltonen; Johanna Schleutker; Pia Vahteristo
Journal:  Eur J Hum Genet       Date:  2008-03-12       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.